Kjell Bjartveit
Research Subjects
Research Interests
Kjell Bjartveit has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
A Tverdal
Norwegian Institute of Public Health, Oslo, Norway
3 shared publications- Aage Tverdal
Norwegian Institute of Public Health, Centre for Fertility and Health, Oslo, Norway
1 shared publication - Einar Heldal
Norwegian Institute of Public Health, Oslo, Norway
1 shared publication
Latest Publications
- Open Access
- 27 November 2006
- Published by BMJ in Tobacco Control
- Vol. 15 (6) , 472-480
Health consequences of reduced daily cigarette consumption
Objective:To determine the risk of dying from specified smoking-related diseases and from any cause in heavy smoking men and women (⩾15 cigarettes/day), who reduced their daily cigarette consumption by >50%.Design:A prospective cohort study.Setting:Three counties in Norway.Participants:24 959 men and 26 251 women, aged 20–49 years, screened for risk factors of cardiovascular disease in the mid-1970s, screened again after 3–13 years, and followed up throughout 2003.Outcomes:Absolute mortality and relative risks adjusted for confounding variables, of dying from all causes, cardiovascular disease, ischaemic heart disease, all smoking-related cancer and lung cancer.Results:With sustained heavy smokers as reference, the smokers of both sexes who reduced their daily consumption (reducers) had the following adjusted relative risks (95% confidence interval (CI)): of dying from any cause, 1.02 (0.84 to 1.22); cardiovascular disease, 1.02 (0.75 to 1.39); ischaemic heart disease, 0.96 (0.65 to 1.41); smoking-related cancer, 0.86 (0.57 to 1.29); and lung cancer, 0.66 (0.36 to 1.21). The difference in cigarette consumption between two examinations was not a significant predictor of death from any of the causes. A follow-up from a third screening of the subgroup who were reducers at both second and third examinations (sustained reducers) did not have a lower risk than those who were heavy smokers at all three examinations.Conclusions:Long-term follow-up provides no evidence that heavy smokers who cut down their daily cigarette consumption by >50% reduce their risk of premature death significantly. In health education and patient counselling, it may give people false expectations to advise that reduction in consumption is associated with reduction in harm.
- 27 November 2006
- Published by BMJ in Tobacco Control
- Vol. 15 (6) , 472-480
Open AccessHealth consequences of reduced daily cigarette consumption
Objective:To determine the risk of dying from specified smoking-related diseases and from any cause in heavy smoking men and women (⩾15 cigarettes/day), who reduced their daily cigarette consumption by >50%.Design:A prospective cohort study.Setting:Three counties in Norway.Participants:24 959 men and 26 251 women, aged 20–49 years, screened for risk factors of cardiovascular disease in the mid-1970s, screened again after 3–13 years, and followed up throughout 2003.Outcomes:Absolute mortality and relative risks adjusted for confounding variables, of dying from all causes, cardiovascular disease, ischaemic heart disease, all smoking-related cancer and lung cancer.Results:With sustained heavy smokers as reference, the smokers of both sexes who reduced their daily consumption (reducers) had the following adjusted relative risks (95% confidence interval (CI)): of dying from any cause, 1.02 (0.84 to 1.22); cardiovascular disease, 1.02 (0.75 to 1.39); ischaemic heart disease, 0.96 (0.65 to 1.41); smoking-related cancer, 0.86 (0.57 to 1.29); and lung cancer, 0.66 (0.36 to 1.21). The difference in cigarette consumption between two examinations was not a significant predictor of death from any of the causes. A follow-up from a third screening of the subgroup who were reducers at both second and third examinations (sustained reducers) did not have a lower risk than those who were heavy smokers at all three examinations.Conclusions:Long-term follow-up provides no evidence that heavy smokers who cut down their daily cigarette consumption by >50% reduce their risk of premature death significantly. In health education and patient counselling, it may give people false expectations to advise that reduction in consumption is associated with reduction in harm.
- 1 February 2006
- Published by BMJ in Tobacco Control
- Vol. 15 (1) , 71-72
Health consequences of smoking 1-4 cigarettes per day: response to G F Cope (eletter to journal)
Dr Cope refers to two papers: a cross sectional randomised study on smoking reduction in pregnant women, and an assessment of smoking status in patients with peripheral arterial disease.2,3 Our study did not concentrate on …
- 1 February 2006
- Published by BMJ in Tobacco Control
- Vol. 15 (1) , 71-72
Health consequences of smoking 1-4 cigarettes per day: response to G F Cope (eletter to journal)
Dr Cope refers to two papers: a cross sectional randomised study on smoking reduction in pregnant women, and an assessment of smoking status in patients with peripheral arterial disease.2,3 Our study did not concentrate on …
- Top Cited PapersOpen Access
- 23 September 2005
- Published by BMJ in Tobacco Control
- Vol. 14 (5) , 315-320
Health consequences of smoking 1–4 cigarettes per day
Objectives:To determine the risk in men and women smoking 1–4 cigarettes per day of dying from specified smoking related diseases and from any cause.Design:Prospective study.Setting:Oslo city and three counties in Norway.Participants:23 521 men and 19 201 women, aged 35–49 years, screened for cardiovascular disease risk factors in the mid 1970s and followed throughout 2002.Outcomes:Absolute mortality and relative risks adjusted for confounding variables, of dying from ischaemic heart disease, all cancer, lung cancer, and from all causes.Results:Adjusted relative risk (95% confidence interval) in smokers of 1–4 cigarettes per day, with never smokers as reference, of dying from ischaemic heart disease was 2.74 (2.07 to 3.61) in men and 2.94 (1.75 to 4.95) in women. The corresponding figures for all cancer were 1.08 (0.78 to 1.49) and 1.14 (0.84 to 1.55), for lung cancer 2.79 (0.94 to 8.28) and 5.03 (1.81 to 13.98), and for any cause 1.57 (1.33 to 1.85) and 1.47 (1.19 to 1.82).Conclusions:In both sexes, smoking 1–4 cigarettes per day was associated with a significantly higher risk of dying from ischaemic heart disease and from all causes, and from lung cancer in women. Smoking control policymakers and health educators should emphasise more strongly that light smokers also endanger their health.
- 23 September 2005
- Published by BMJ in Tobacco Control
- Vol. 14 (5) , 315-320
Top Cited PapersOpen AccessHealth consequences of smoking 1–4 cigarettes per day
Objectives:To determine the risk in men and women smoking 1–4 cigarettes per day of dying from specified smoking related diseases and from any cause.Design:Prospective study.Setting:Oslo city and three counties in Norway.Participants:23 521 men and 19 201 women, aged 35–49 years, screened for cardiovascular disease risk factors in the mid 1970s and followed throughout 2002.Outcomes:Absolute mortality and relative risks adjusted for confounding variables, of dying from ischaemic heart disease, all cancer, lung cancer, and from all causes.Results:Adjusted relative risk (95% confidence interval) in smokers of 1–4 cigarettes per day, with never smokers as reference, of dying from ischaemic heart disease was 2.74 (2.07 to 3.61) in men and 2.94 (1.75 to 4.95) in women. The corresponding figures for all cancer were 1.08 (0.78 to 1.49) and 1.14 (0.84 to 1.55), for lung cancer 2.79 (0.94 to 8.28) and 5.03 (1.81 to 13.98), and for any cause 1.57 (1.33 to 1.85) and 1.47 (1.19 to 1.82).Conclusions:In both sexes, smoking 1–4 cigarettes per day was associated with a significantly higher risk of dying from ischaemic heart disease and from all causes, and from lung cancer in women. Smoking control policymakers and health educators should emphasise more strongly that light smokers also endanger their health.
- 1 April 2003
- Vol. 7 (4) , 306-11
Olaf Scheel and Johannes Heimbeck: their contribution to understanding the pathogenesis and prevention of tuberculosis.
From 1924 onwards, mandatory tuberculin testing (von Pirquet's method) was introduced for student nurses on entry to the Ullevaal Hospital School of Nursing, Oslo. The chief physician of the hospital's Department IX, Olaf Scheel, was responsible for this measure. In 1927, his deputy Johannes Heimbeck showed that about half of the students were not infected at the time of entry, a conclusion that was in fundamental conflict with the prevailing view that nearly all tuberculous infection occurred in childhood. Virtually all tuberculin-negative student nurses, however, became infected during their 3-year training. These findings changed our understanding of the pathogenesis of tuberculosis. BCG vaccination had recently been introduced by Calmette. From 1927 onwards Heimbeck offered BCG vaccination to tuberculin-negative student nurses, while Scheel undertook a similar project among medical students. The two projects continued until respectively 1936 and 1939. Long-term follow-up of both groups demonstrated a protective effect of about 80% in those accepting vaccination. Calmette had given the vaccine per os to new-born babies. Heimbeck and Scheel pioneered giving the vaccine via injection and to adults. These projects have been criticised for being based on voluntary inclusion and not being conducted as randomised control trials. The results were so convincing, however, that they led to the launch of the Norwegian BCG programme shortly after World War II. Scheel and Heimbeck' efforts were also of great importance for the use of the BCG vaccine in other countries.
- 1 April 2003
- Vol. 7 (4) , 306-11
Olaf Scheel and Johannes Heimbeck: their contribution to understanding the pathogenesis and prevention of tuberculosis.
From 1924 onwards, mandatory tuberculin testing (von Pirquet's method) was introduced for student nurses on entry to the Ullevaal Hospital School of Nursing, Oslo. The chief physician of the hospital's Department IX, Olaf Scheel, was responsible for this measure. In 1927, his deputy Johannes Heimbeck showed that about half of the students were not infected at the time of entry, a conclusion that was in fundamental conflict with the prevailing view that nearly all tuberculous infection occurred in childhood. Virtually all tuberculin-negative student nurses, however, became infected during their 3-year training. These findings changed our understanding of the pathogenesis of tuberculosis. BCG vaccination had recently been introduced by Calmette. From 1927 onwards Heimbeck offered BCG vaccination to tuberculin-negative student nurses, while Scheel undertook a similar project among medical students. The two projects continued until respectively 1936 and 1939. Long-term follow-up of both groups demonstrated a protective effect of about 80% in those accepting vaccination. Calmette had given the vaccine per os to new-born babies. Heimbeck and Scheel pioneered giving the vaccine via injection and to adults. These projects have been criticised for being based on voluntary inclusion and not being conducted as randomised control trials. The results were so convincing, however, that they led to the launch of the Norwegian BCG programme shortly after World War II. Scheel and Heimbeck' efforts were also of great importance for the use of the BCG vaccine in other countries.
- 30 March 2001
- Vol. 121 (9) , 1076-81
[Olaf Scheel and Johannes Heimbeck and their work with the BCG vaccine].
From 1924 and onwards, obligatory tuberculin test (Pirquet's method) was introduced at the time when student nurses commenced their training at Ullevål Hospital's school of nursing. Chief physician of the hospital's department IX, Olaf Scheel, was responsible for this measure. In 1927, his deputy, Johannes Heimbeck, showed that about half of the students were not infected at the time of school entrance. This conclusion was in fundamental conflict with the prevailing view that nearly all tuberculous infection took place in childhood. Virtually all Pirquet-negative student nurses were, however, infected in the course of the three-year training period. BCG vaccine had recently been introduced by Calmette. From 1927 onwards, Heimbeck offered BCG vaccination to the Pirquet-negative student nurses, while Scheel undertook a similar project among medical students. The two projects went on to 1936 and 1939. Follow up of both groups demonstrated a protective effect of about 80 per cent. Calmette had given the vaccine per os to new-born babies. Heimbeck and Scheel pioneered by giving the vaccine by injection and to adults. The projects have been criticised for being based on voluntary attendance and not conducted as randomised control trials. The results, however, were so convincing that they became decisive for the Norwegian BCG programme that was launched shortly after the Second World War. The efforts by Scheel and Heimbeck were also of great importance to the use of BCG vaccine in other countries.
- 30 March 2001
- Vol. 121 (9) , 1076-81
[Olaf Scheel and Johannes Heimbeck and their work with the BCG vaccine].
From 1924 and onwards, obligatory tuberculin test (Pirquet's method) was introduced at the time when student nurses commenced their training at Ullevål Hospital's school of nursing. Chief physician of the hospital's department IX, Olaf Scheel, was responsible for this measure. In 1927, his deputy, Johannes Heimbeck, showed that about half of the students were not infected at the time of school entrance. This conclusion was in fundamental conflict with the prevailing view that nearly all tuberculous infection took place in childhood. Virtually all Pirquet-negative student nurses were, however, infected in the course of the three-year training period. BCG vaccine had recently been introduced by Calmette. From 1927 onwards, Heimbeck offered BCG vaccination to the Pirquet-negative student nurses, while Scheel undertook a similar project among medical students. The two projects went on to 1936 and 1939. Follow up of both groups demonstrated a protective effect of about 80 per cent. Calmette had given the vaccine per os to new-born babies. Heimbeck and Scheel pioneered by giving the vaccine by injection and to adults. The projects have been criticised for being based on voluntary attendance and not conducted as randomised control trials. The results, however, were so convincing that they became decisive for the Norwegian BCG programme that was launched shortly after the Second World War. The efforts by Scheel and Heimbeck were also of great importance to the use of BCG vaccine in other countries.
- 10 November 1995
- Vol. 115 (27) , 3390-3
[Tuberculosis trends in Norway--has the decline stopped?].
The aim of the study was to present the trend as regards tuberculosis in Norway since 1950, on the basis of data on incidence and mortality in the total population and infection rate among pupils leaving primary school. The decline in incidence continued until the late 1980s. While the decline was 11% per year during the period 1950-74, it has been slower in recent years. In 1990-92 the incidence level was somewhat higher than in 1989, but figures for 1993-94 indicate a new decline. Mortality declined more slowly after the mid-1970s; a similar trend is found for prevalence of infection among pupils. The incidence is among the lowest in Europe. The proportion of cases among immigrants increased gradually from 4% in 1977 to 40% in 1993. Among the Norwegian-born population the incidence rate of infectious pulmonary tuberculosis has shown a steady decline, also during the last decades. Norwegian-born cases are mainly elderly persons infected many decades ago. New infection is probably rare, and the proportion of infected persons is gradually declining.
- 10 November 1995
- Vol. 115 (27) , 3390-3
[Tuberculosis trends in Norway--has the decline stopped?].
The aim of the study was to present the trend as regards tuberculosis in Norway since 1950, on the basis of data on incidence and mortality in the total population and infection rate among pupils leaving primary school. The decline in incidence continued until the late 1980s. While the decline was 11% per year during the period 1950-74, it has been slower in recent years. In 1990-92 the incidence level was somewhat higher than in 1989, but figures for 1993-94 indicate a new decline. Mortality declined more slowly after the mid-1970s; a similar trend is found for prevalence of infection among pupils. The incidence is among the lowest in Europe. The proportion of cases among immigrants increased gradually from 4% in 1977 to 40% in 1993. Among the Norwegian-born population the incidence rate of infectious pulmonary tuberculosis has shown a steady decline, also during the last decades. Norwegian-born cases are mainly elderly persons infected many decades ago. New infection is probably rare, and the proportion of infected persons is gradually declining.